Anti-allergic function and regulatory mechanisms of KR62980 in allergen-induced airway inflammation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Won, Hee Yeon | - |
dc.contributor.author | Min, Hyun Jung | - |
dc.contributor.author | Ahn, Jin Hee | - |
dc.contributor.author | Yoo, Sung-Eun | - |
dc.contributor.author | Bae, Myung Ae | - |
dc.contributor.author | Hong, Jeong-Ho | - |
dc.contributor.author | Hwang, Eun Sook | - |
dc.date.accessioned | 2021-09-08T04:31:45Z | - |
dc.date.available | 2021-09-08T04:31:45Z | - |
dc.date.created | 2021-06-11 | - |
dc.date.issued | 2010-03-15 | - |
dc.identifier.issn | 0006-2952 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/116799 | - |
dc.description.abstract | The ligand-activated transcription factor, peroxisome proliferator-activated receptor (PPAR)gamma, and its ligands inhibit pro-inflammatory cytokine production by immune cells, thus exerting anti-inflammatory activity. As a non-thiazolidinedione PPAR gamma ligand, KR62980 has anti-diabetic and anti-adipogenic activities, but its anti-inflammatory function has yet to be characterized. In this study, we investigated the functions and mechanisms of KR62980 in the activation and differentiation of CD4+ T helper (Th) cells by comparing its effects with those of a thiazolidinedione PPAR gamma ligand, rosiglitazone. KR62980 dose-dependently and significantly suppressed TCR-triggered Th cell proliferation by suppressing IL-2/IL-2R alpha-mediated signaling. Both KR62980 and rosiglitazone suppressed IFN gamma production in a close-dependent manner, whereas IL-4 gene expression was specifically suppressed by only KR62980. In addition, sustained KR62980 treatment diminished Th2 cytokine production by inhibiting c-Maf expression. In vivo administration of KR62980 in a model of allergic asthma significantly attenuated eotaxin-induced eosinophil infiltration, allergic cytokine production and collagen deposition in the lung. KR62980 also decreased goblet cell hyperplasia in the airway and mucous cell metaplasia in nasal epithelium, concurrent with decreases of allergic Th2 cytokines and IL-17 in the draining lymph node. In conclusion, a novel PPAR gamma ligand, KR62980, suppresses in vitro Th2 cell differentiation and attenuates in vivo OVA-induced airway inflammation, suggesting a beneficial role for KR62980 in the treatment of allergic asthma and allergic rhinitis. (C) 2009 Elsevier Inc. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | PERGAMON-ELSEVIER SCIENCE LTD | - |
dc.subject | ACTIVATED-RECEPTOR-GAMMA | - |
dc.subject | T-CELL PROLIFERATION | - |
dc.subject | PPAR-GAMMA | - |
dc.subject | THERAPEUTIC TARGET | - |
dc.subject | MURINE MODEL | - |
dc.subject | C-MAF | - |
dc.subject | LIGANDS | - |
dc.subject | AGONIST | - |
dc.subject | INSULIN | - |
dc.subject | INHIBITION | - |
dc.title | Anti-allergic function and regulatory mechanisms of KR62980 in allergen-induced airway inflammation | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Hong, Jeong-Ho | - |
dc.identifier.doi | 10.1016/j.bcp.2009.10.023 | - |
dc.identifier.scopusid | 2-s2.0-74149086222 | - |
dc.identifier.wosid | 000274165500010 | - |
dc.identifier.bibliographicCitation | BIOCHEMICAL PHARMACOLOGY, v.79, no.6, pp.888 - 896 | - |
dc.relation.isPartOf | BIOCHEMICAL PHARMACOLOGY | - |
dc.citation.title | BIOCHEMICAL PHARMACOLOGY | - |
dc.citation.volume | 79 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 888 | - |
dc.citation.endPage | 896 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | ACTIVATED-RECEPTOR-GAMMA | - |
dc.subject.keywordPlus | T-CELL PROLIFERATION | - |
dc.subject.keywordPlus | PPAR-GAMMA | - |
dc.subject.keywordPlus | THERAPEUTIC TARGET | - |
dc.subject.keywordPlus | MURINE MODEL | - |
dc.subject.keywordPlus | C-MAF | - |
dc.subject.keywordPlus | LIGANDS | - |
dc.subject.keywordPlus | AGONIST | - |
dc.subject.keywordPlus | INSULIN | - |
dc.subject.keywordPlus | INHIBITION | - |
dc.subject.keywordAuthor | KR62980 | - |
dc.subject.keywordAuthor | PPAR gamma | - |
dc.subject.keywordAuthor | Rosiglitazone | - |
dc.subject.keywordAuthor | Th2 cell | - |
dc.subject.keywordAuthor | Allergic airway inflammation | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.